Cargando…

Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma

Individually, tissue and soluble markers involved in the programmed cell death protein 1/programmed death‐ligand (PD‐1/PD‐L) axis have been described as biomarkers with clinical value in classical Hodgkin lymphoma (cHL). In the context of the success of immune checkpoint blockade therapy in cHL, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Veldman, Johanna, Alsada, Zainab N. D., van den Berg, Anke, Plattel, Wouter J., Diepstra, Arjan, Visser, Lydia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247981/
https://www.ncbi.nlm.nih.gov/pubmed/33620088
http://dx.doi.org/10.1111/bjh.17362
_version_ 1783716627657785344
author Veldman, Johanna
Alsada, Zainab N. D.
van den Berg, Anke
Plattel, Wouter J.
Diepstra, Arjan
Visser, Lydia
author_facet Veldman, Johanna
Alsada, Zainab N. D.
van den Berg, Anke
Plattel, Wouter J.
Diepstra, Arjan
Visser, Lydia
author_sort Veldman, Johanna
collection PubMed
description Individually, tissue and soluble markers involved in the programmed cell death protein 1/programmed death‐ligand (PD‐1/PD‐L) axis have been described as biomarkers with clinical value in classical Hodgkin lymphoma (cHL). In the context of the success of immune checkpoint blockade therapy in cHL, it is interesting to discover whether plasma levels of proteins in the PD‐1/PD‐L axis are a reflection of expression by the corresponding tissue. Paired tissue and plasma samples of cHL patients were collected and analysed for PD‐1, PD‐L1 and PD‐L2 levels. In addition, vascular endothelial growth factor (VEGF) and CD83, molecules regarded to influence the expression of PD‐1, PD‐L1 and/or PD‐L2, were included. PD‐L1 was upregulated in the plasma of cHL patients compared to healthy controls and correlated well with several clinical parameters. Strong PD‐L1 expression in the tumour microenvironment contributed to high soluble (s)PD‐L1 levels, although there was no direct correlation between plasma PD‐L1 levels and total expression of PD‐L1 in corresponding cHL tissue. Interestingly, we observed a positive correlation between VEGF and PD‐1 levels in both tissue and plasma. In conclusion, although PD‐L1 is a promising soluble biomarker in cHL, its levels do not reflect the total tissue expression. Future studies focusing on PD‐L1 as a predictor for immune checkpoint treatment response, should include both biopsy and plasma samples.
format Online
Article
Text
id pubmed-8247981
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82479812021-07-02 Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma Veldman, Johanna Alsada, Zainab N. D. van den Berg, Anke Plattel, Wouter J. Diepstra, Arjan Visser, Lydia Br J Haematol Haematological Malignancy – Clinical Individually, tissue and soluble markers involved in the programmed cell death protein 1/programmed death‐ligand (PD‐1/PD‐L) axis have been described as biomarkers with clinical value in classical Hodgkin lymphoma (cHL). In the context of the success of immune checkpoint blockade therapy in cHL, it is interesting to discover whether plasma levels of proteins in the PD‐1/PD‐L axis are a reflection of expression by the corresponding tissue. Paired tissue and plasma samples of cHL patients were collected and analysed for PD‐1, PD‐L1 and PD‐L2 levels. In addition, vascular endothelial growth factor (VEGF) and CD83, molecules regarded to influence the expression of PD‐1, PD‐L1 and/or PD‐L2, were included. PD‐L1 was upregulated in the plasma of cHL patients compared to healthy controls and correlated well with several clinical parameters. Strong PD‐L1 expression in the tumour microenvironment contributed to high soluble (s)PD‐L1 levels, although there was no direct correlation between plasma PD‐L1 levels and total expression of PD‐L1 in corresponding cHL tissue. Interestingly, we observed a positive correlation between VEGF and PD‐1 levels in both tissue and plasma. In conclusion, although PD‐L1 is a promising soluble biomarker in cHL, its levels do not reflect the total tissue expression. Future studies focusing on PD‐L1 as a predictor for immune checkpoint treatment response, should include both biopsy and plasma samples. John Wiley and Sons Inc. 2021-02-23 2021-05 /pmc/articles/PMC8247981/ /pubmed/33620088 http://dx.doi.org/10.1111/bjh.17362 Text en © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Haematological Malignancy – Clinical
Veldman, Johanna
Alsada, Zainab N. D.
van den Berg, Anke
Plattel, Wouter J.
Diepstra, Arjan
Visser, Lydia
Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
title Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
title_full Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
title_fullStr Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
title_full_unstemmed Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
title_short Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
title_sort soluble pd‐l1 is a promising disease biomarker but does not reflect tissue expression in classic hodgkin lymphoma
topic Haematological Malignancy – Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247981/
https://www.ncbi.nlm.nih.gov/pubmed/33620088
http://dx.doi.org/10.1111/bjh.17362
work_keys_str_mv AT veldmanjohanna solublepdl1isapromisingdiseasebiomarkerbutdoesnotreflecttissueexpressioninclassichodgkinlymphoma
AT alsadazainabnd solublepdl1isapromisingdiseasebiomarkerbutdoesnotreflecttissueexpressioninclassichodgkinlymphoma
AT vandenberganke solublepdl1isapromisingdiseasebiomarkerbutdoesnotreflecttissueexpressioninclassichodgkinlymphoma
AT plattelwouterj solublepdl1isapromisingdiseasebiomarkerbutdoesnotreflecttissueexpressioninclassichodgkinlymphoma
AT diepstraarjan solublepdl1isapromisingdiseasebiomarkerbutdoesnotreflecttissueexpressioninclassichodgkinlymphoma
AT visserlydia solublepdl1isapromisingdiseasebiomarkerbutdoesnotreflecttissueexpressioninclassichodgkinlymphoma